Patient Perspectives on Bladder Cancer
Elizabeth R. Plimack, MD, MS, FASCO
Lillibeth Velasco, MSN, RN
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Reviewing the Latest Bladder Cancer Practice Guidelines
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Diagnosis and Management of Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Expert Viewpoint: Optimizing Breast Cancer Treatment
Erica L. Mayer, MD, MPH
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Alan Venook, MD
Management of HER2-Low MBC Following First-Line Disease Progression
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.